Stories of ineffective or underdosed products appear regularly
In 2019, an open-label randomised trial conducted for 48 weeks, including patients with biopsy-proven MASH, demonstrated that the association between N-acetylcysteine and metformin could reduce liver disease activity in patients with MASH, testified by the improvement in ballooning and NAS [127], and in a randomised, double-blind, placebo-controlled trial conducted on 173 children affected by MASLD, metformin (0.3 vs
Mechanism of Action (Based on Research) The combination of BPC-157 and TB-500 has drawn interest in preclinical studies due to their complementary mechanisms in supporting tissue repair, cellular regeneration, and inflammation control
Dehydration risk increases with gastrointestinal side effects, particularly in older adults or those with renal impairment
Sustainable weight management typically depends on a combination of nutrition guidance, physical activity, lifestyle modification, and medical oversight
